{"groups":[{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 70 mg QD for 28 days and lenalidomide 15 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).","id":"FG000","title":"Dasatinib 70 mg + Lenalidomide 15 mg + Dexamethasone 40 mg"},{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 70 mg QD for 28 days and lenalidomide 20 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).","id":"FG001","title":"Dasatinib 70 mg + Lenalidomide 20 mg + Dexamethasone 40 mg"},{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 100 mg QD for 28 days and lenalidomide 20 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).","id":"FG002","title":"Dasatinib 100 mg + Lenalidomide 20 mg + Dexamethasone 40 mg"},{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 100 mg QD for 28 days and lenalidomide 25 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22).","id":"FG003","title":"Dasatinib 100 mg + Lenalidomide 25 mg + Dexamethasone 40 mg"},{"description":"Participants were treated with a combination of dasatinib, lenalidomide and dexamethasone in 28 day cycles (dasatinib 140 mg QD for 28 days and lenalidomide 25 mg QD for 21 days, along with 40 mg QD of dexamethasone given weekly on Days 1, 8, 15, and 22). Cohort includes 4 participants treated for dose -finding phase and 13 participants treated in dose expansion phase.","id":"FG004","title":"Dasatinib 140 mg + Lenalidomide 25 mg + Dexamethasone 40 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"}],"type":"Still on treatment"}],"milestones":[{"achievements":[{"comment":"Participants who received treatment","groupId":"FG000","numSubjects":"6"},{"comment":"Participants who received treatment","groupId":"FG001","numSubjects":"3"},{"comment":"Participants who received treatment","groupId":"FG002","numSubjects":"3"},{"comment":"Participants who received treatment","groupId":"FG003","numSubjects":"6"},{"comment":"Participants who received treatment","groupId":"FG004","numSubjects":"17"}],"type":"STARTED"},{"achievements":[{"comment":"Completed=off treatment;Disease progression-1;Death-1;Max. clinical benefit-2;Study drug toxicity-2","groupId":"FG000","numSubjects":"6"},{"comment":"Completed=off treatment; Disease progression-1;Death-1; Unrelated AE-1","groupId":"FG001","numSubjects":"3"},{"comment":"Completed=off treatment; Disease progression-1;Maximum clinical benefit-1; Unrelated AE-1","groupId":"FG002","numSubjects":"3"},{"comment":"Completed=off treatment; Disease progression-2; Unrelated AE 1 and Subject request 2","groupId":"FG003","numSubjects":"5"},{"comment":"Completed=offtreatment;Disease progression-6;Study drug toxicity-7; Unrelated AE-1,Subject request-1","groupId":"FG004","numSubjects":"15"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Of 39 participants were enrolled in this study, 4 never received treatment due to screening failure. A total of 35 participants received treatment."}